|Articles|July 17, 2019

Real-World Data: Exploring Possibilities and Overcoming Obstacles

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Launch is Just the Beginning: Rare Disease Care Requires Durability

ByBansi Nagji, CEO, PANTHERx Rare

July 7th 2026

Sponsored

Woman with short straight blonde hair, black glasses, and blue shirt smiles in front of an Acumetis blue background

Access by Design: Embedding Market Access Thinking Across the Drug Development Lifecycle

ByEsther Nzenza, Senior Partner and Global Head of Value and Access,Acumetis

Published: June 26th 2026 | Updated: June 30th 2026

Sponsored

A man with light hair and blue eyes stands in front of a LogiPharma background in a gray suit and white collared shirt

Improving Global Pharma Operations with Data

ByChristoph Bamert, Chief Sales Officer,ELPRO-BUCHS AG, Switzerland

June 10th 2026

Sponsored

Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

What Specialty Access Looks Like When It’s Built to Scale

ByMiranda Delatore, DNP, RN, NEA‑BC, CoverMyMeds

June 9th 2026

Sponsored

Two men, one with brown hair, is gesturing towards a bald man in conversation. They are both wearing Inizio Engage t-shirts.

An End-to-End Approach to Specialty Patient Services

ByJason Rains, Senior Vice President, Patient Access,Randy Quist, Vice President, Field Reimbursement,Inizio Engage

June 3rd 2026

Sponsored

Real-World Data: Exploring Possibilities and Overcoming Obstacles

Related Content

Launch is Just the Beginning: Rare Disease Care Requires Durability

Access by Design: Embedding Market Access Thinking Across the Drug Development Lifecycle

Improving Global Pharma Operations with Data

What Specialty Access Looks Like When It’s Built to Scale

An End-to-End Approach to Specialty Patient Services

Trending on PharmExec

Modern Policy Concerns Stemming from 340B

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

2026 Emerging Pharma Leaders

Preventing Cardiovascular Disease Through Mission-Driven Leadership

What C-Suite Readiness Really Requires